Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285126 · ClinicalTrials.gov registry record
Pompe Gene Therapy- Screening for Eligibility
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 19
- Enrollment target
NCT03285126 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 19 participants.
The verdict
NCT03285126 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine eligibility for the future clinical trial of gene therapy in adults with late-onset Pompe disease. This screening protocol will enroll up to 20 adults patients (\>=18 yo) with late-onset Pompe disease. Study assessments include review of medical history, vital signs, physical examination, muscle function testing, lung function testing, blood and urine collection, serum pregnancy test and ECG. The study results will be collected to perform descriptive statistical analysis and used to determine eligibility for the proposed clinical trial of gene therapy in the future.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2019-06-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03285126
The ClinicalTrials.gov registry entry for NCT03285126 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03285126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03285126 about?
NCT03285126 is a clinical study titled "Pompe Gene Therapy- Screening for Eligibility". The purpose of this study is to determine eligibility for the future clinical trial of gene therapy in adults with late-onset Pompe disease. This screening protocol will enroll up to 20 adults patients (\>=18 yo) with late-onset Pompe disease. Study assessments include review of medical history, vi...
What is the current status of trial NCT03285126?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2017-11-01. Estimated completion is 2019-06-29.
Who is sponsoring clinical trial NCT03285126?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.